Supernus Pharmaceuticals, Inc.
SUPN
$44.88
$1.563.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -1.71% | 4.30% | 5.99% | 14.17% | 24.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.71% | 4.30% | 5.99% | 14.17% | 24.17% |
| Cost of Revenue | -6.08% | -3.35% | 32.97% | -10.30% | -15.05% |
| Gross Profit | -1.19% | 5.28% | 2.33% | 17.74% | 31.39% |
| SG&A Expenses | 10.07% | 9.05% | 0.40% | -1.75% | -1.01% |
| Depreciation & Amortization | 3.54% | -1.74% | -13.41% | -8.26% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.80% | 6.04% | 6.38% | 0.79% | -1.48% |
| Operating Income | -38.83% | -64.69% | 3.01% | 268.77% | 208.44% |
| Income Before Tax | -36.62% | -2,499.59% | 2,564.85% | 354.47% | 253.57% |
| Income Tax Expenses | -191.29% | 4,938.66% | 6,075.14% | -75.08% | 139.19% |
| Earnings from Continuing Operations | 12.97% | -9,637.90% | 1,204.51% | 340.97% | 2,496.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.97% | -9,637.90% | 1,204.51% | 340.97% | 2,496.63% |
| EBIT | -38.83% | -64.69% | 3.01% | 268.77% | 208.44% |
| EBITDA | -16.52% | -18.87% | -5.56% | 63.96% | 891.14% |
| EPS Basic | 10.88% | -9,304.35% | 1,185.58% | 338.55% | 2,482.89% |
| Normalized Basic EPS | -29.94% | -196.91% | 15.21% | 240.28% | 233.21% |
| EPS Diluted | 11.11% | -9,722.73% | 1,446.86% | 335.82% | 1,900.00% |
| Normalized Diluted EPS | -29.77% | -200.00% | 14.51% | 235.00% | 231.45% |
| Average Basic Shares Outstanding | 1.90% | 1.94% | 1.50% | 0.99% | 0.87% |
| Average Diluted Shares Outstanding | 1.65% | 0.43% | 2.10% | 2.58% | 2.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |